Tatjana Antic to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Tatjana Antic has written about TOR Serine-Threonine Kinases.
Connection Strength
2.685
-
MTOR-mutated eosinophilic renal cell carcinomas with loss of chromosome 1 and high metastatic potential: further expanding the spectrum of TSC/mTOR pathway mutated renal tumors. Virchows Arch. 2026 Sep; 489(3):575-581.
Score: 0.820
-
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
Score: 0.586
-
Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
Score: 0.564
-
Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. Hum Pathol. 2026 Sep; 175:106154.
Score: 0.212
-
Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature. Hum Pathol. 2024 Nov; 153:105680.
Score: 0.191
-
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol. 2023 04; 134:124-133.
Score: 0.168
-
TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol. 2021 09; 115:84-95.
Score: 0.146